[Vedolizumab in Crohn Disease genesis-sefh drug evaluation report]

Farm Hosp. 2015 Sep 1;39(5):297-308. doi: 10.7399/fh.2015.39.5.8981.

[Article in Spanish]

Authors

Jenifer González Chávez¹, Rocio Asensi Diez¹, Rocío Tamayo Bermejo¹, Emilio Jesús Alegre Del Rey², Noemí Martínez López de Castro³

Affiliations

¹ Hospital Regional Universitario de Málaga, Málaga.. rocio.asensi.sspa@juntadeandalucia.es.
² Hospital Universitario de Puerto Real, Cádiz.. rocio.asensi.sspa@juntadeandalucia.es.
³ Hospital de Meixoeiro, Vigo. Spain.. rocio.asensi.sspa@juntadeandalucia.es.

PMID: 26546942
DOI: 10.7399/fh.2015.39.5.8981

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / economics
Antibodies, Monoclonal, Humanized / therapeutic use*
Crohn Disease / drug therapy*
Crohn Disease / economics
Drug Evaluation
Humans
Immunosuppressive Agents / economics
Immunosuppressive Agents / therapeutic use*
Multicenter Studies as Topic
Randomized Controlled Trials as Topic

Substances

Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
vedolizumab